Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Chlorbipram: a novel PDE4 inhibitor with improved safety as a potential antidepressant and cognitive enhancer.

Zhang MZ, Zhou ZZ, Yuan X, Cheng YF, Bi BT, Gong MF, Chen YP, Xu JP.

Eur J Pharmacol. 2013 Dec 5;721(1-3):56-63. doi: 10.1016/j.ejphar.2013.09.055.

PMID:
24113523
2.

RNA interference-mediated phosphodiesterase 4D splice variants knock-down in the prefrontal cortex produces antidepressant-like and cognition-enhancing effects.

Wang ZZ, Zhang Y, Liu YQ, Zhao N, Zhang YZ, Yuan L, An L, Li J, Wang XY, Qin JJ, Wilson SP, O'Donnell JM, Zhang HT, Li YF.

Br J Pharmacol. 2013 Feb;168(4):1001-14. doi: 10.1111/j.1476-5381.2012.02225.x.

3.

Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats.

Zhang HT, Zhao Y, Huang Y, Deng C, Hopper AT, De Vivo M, Rose GM, O'Donnell JM.

Psychopharmacology (Berl). 2006 Jun;186(2):209-17.

PMID:
16586089
4.

Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme.

Zhang HT, Huang Y, Jin SL, Frith SA, Suvarna N, Conti M, O'Donnell JM.

Neuropsychopharmacology. 2002 Oct;27(4):587-95.

5.

The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses.

Vanmierlo T, Creemers P, Akkerman S, van Duinen M, Sambeth A, De Vry J, Uz T, Blokland A, Prickaerts J.

Behav Brain Res. 2016 Apr 15;303:26-33. doi: 10.1016/j.bbr.2016.01.031.

PMID:
26794595
6.

Interaction between the antidepressant-like behavioral effects of beta adrenergic agonists and the cyclic AMP PDE inhibitor rolipram in rats.

Zhang HT, Huang Y, Mishler K, Roerig SC, O'Donnell JM.

Psychopharmacology (Berl). 2005 Oct;182(1):104-15.

PMID:
16010541
7.

Antidepressant-like effect of etazolate, a cyclic nucleotide phosphodiesterase 4 inhibitor--an approach using rodent behavioral antidepressant tests battery.

Jindal A, Mahesh R, Gautam B, Bhatt S, Pandey D.

Eur J Pharmacol. 2012 Aug 15;689(1-3):125-31. doi: 10.1016/j.ejphar.2012.05.051.

PMID:
22698578
8.

Prevention of cerebral ischemia-induced memory deficits by inhibition of phosphodiesterase-4 in rats.

Li LX, Cheng YF, Lin HB, Wang C, Xu JP, Zhang HT.

Metab Brain Dis. 2011 Mar;26(1):37-47. doi: 10.1007/s11011-011-9235-0.

PMID:
21327879
9.

The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.

Davis TG, Peterson JJ, Kou JP, Capper-Spudich EA, Ball D, Nials AT, Wiseman J, Solanke YE, Lucas FS, Williamson RA, Ferrari L, Wren P, Knowles RG, Barnette MS, Podolin PL.

J Pharmacol Exp Ther. 2009 Sep;330(3):922-31. doi: 10.1124/jpet.109.152454.

10.

Assessing the emetic potential of PDE4 inhibitors in rats.

Robichaud A, Savoie C, Stamatiou PB, Lachance N, Jolicoeur P, Rasori R, Chan CC.

Br J Pharmacol. 2002 Jan;135(1):113-8.

11.

GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species.

Rutter AR, Poffe A, Cavallini P, Davis TG, Schneck J, Negri M, Vicentini E, Montanari D, Arban R, Gray FA, Davies CH, Wren PB.

J Pharmacol Exp Ther. 2014 Jul;350(1):153-63. doi: 10.1124/jpet.114.214155.

12.
13.

Pharmacology of a novel, orally active PDE4 inhibitor.

Dastidar SG, Ray A, Shirumalla R, Rajagopal D, Chaudhary S, Nanda K, Sharma P, Seth MK, Balachandran S, Gupta N, Palle V.

Pharmacology. 2009;83(5):275-86. doi: 10.1159/000209608.

PMID:
19321962
14.
15.

Behavioral effects of family-selective inhibitors of cyclic nucleotide phosphodiesterases.

O'Donnell JM, Frith S.

Pharmacol Biochem Behav. 1999 May;63(1):185-92.

PMID:
10340540
16.

Differential effects of PDE4 inhibitors on cortical neurons and T-lymphocytes.

Hirose R, Manabe H, Yanagawa K, Ohshima E, Ichimura M.

J Pharmacol Sci. 2008 Feb;106(2):310-7.

17.

Effects of repeated treatment with phosphodiesterase-4 inhibitors on cAMP signaling, hippocampal cell proliferation, and behavior in the forced-swim test.

Xiao L, O'Callaghan JP, O'Donnell JM.

J Pharmacol Exp Ther. 2011 Aug;338(2):641-7. doi: 10.1124/jpet.111.179358.

18.

Long-term cognitive dysfunction in the rat following docetaxel treatment is ameliorated by the phosphodiesterase-4 inhibitor, rolipram.

Callaghan CK, O'Mara SM.

Behav Brain Res. 2015 Sep 1;290:84-9. doi: 10.1016/j.bbr.2015.04.044.

PMID:
25940764
19.

Phosphodiesterases do not limit beta1-adrenoceptor-mediated sinoatrial tachycardia: evidence with PDE3 and PDE4 in rabbits and PDE1-5 in rats.

Kaumann AJ, Galindo-Tovar A, Escudero E, Vargas ML.

Naunyn Schmiedebergs Arch Pharmacol. 2009 Nov;380(5):421-30. doi: 10.1007/s00210-009-0445-5.

PMID:
19693491
20.

PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway.

Robichaud A, Savoie C, Stamatiou PB, Tattersall FD, Chan CC.

Neuropharmacology. 2001;40(2):262-9.

PMID:
11114405

Supplemental Content

Support Center